DERM - Dermira, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
9.62
-0.28 (-2.83%)
As of 12:01PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close9.90
Open9.90
Bid9.50 x 800
Ask9.54 x 1800
Day's Range9.39 - 9.95
52 Week Range6.00 - 15.48
Volume192,020
Avg. Volume946,231
Market Cap516.283M
Beta (3Y Monthly)1.98
PE Ratio (TTM)N/A
EPS (TTM)-5.35
Earnings DateAug 7, 2017 - Aug 11, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.50
Trade prices are not sourced from all markets
  • Business Wire13 days ago

    Dermira to Present at the Raymond James Life Sciences and MedTech Conference

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that company management will present at the Raymond James Life Sciences and MedTech Conference in New York on June 18, 2019 at 2:25 p.m. ET. Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. Dermira is committed to understanding the needs of both patients and physicians and using its insight to identify, develop and commercialize leading-edge medical dermatology products.

  • Markit13 days ago

    See what the IHS Markit Score report has to say about Dermira Inc.

    Dermira Inc NASDAQ/NGS:DERMView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for DERM with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding DERM is favorable, with net inflows of $2.36 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • TheStreet.com18 days ago

    Dermira Advances on Analyst Upgrade to Buy

    climbed 3.4% to $9.29 Thursday after Mizuho upgraded shares of the biopharmaceutical company to buy from neutral. Analyst Irina Koffler also lowered her price target for the Menlo Park, California-based company to $14 from $17 a share.

  • Thomson Reuters StreetEvents20 days ago

    Edited Transcript of DERM earnings conference call or presentation 7-May-19 8:30pm GMT

    Q1 2019 Dermira Inc Earnings Call

  • Dermira (DERM) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Dermira (DERM) Q1 2019 Earnings Call Transcript

    DERM earnings call for the period ending March 31, 2019.

  • Did You Manage To Avoid Dermira's (NASDAQ:DERM) Painful 63% Share Price Drop?
    Simply Wall St.2 months ago

    Did You Manage To Avoid Dermira's (NASDAQ:DERM) Painful 63% Share Price Drop?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! It is doubtless a positive to see that the Dermira, Inc. (NASDAQ:DERM) share price has gained some...

  • Dermira (DERM) Reports Q1 Loss, Lags Revenue Estimates
    Zacks2 months ago

    Dermira (DERM) Reports Q1 Loss, Lags Revenue Estimates

    Dermira (DERM) delivered earnings and revenue surprises of -13.74% and -6.77%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Dermira: 1Q Earnings Snapshot

    The Menlo Park, California-based company said it had a loss of $1.49 per share. The skin condition drug developer posted revenue of $2.5 million in the period, falling short of Street forecasts. Three ...

  • Business Wire2 months ago

    Dermira Reports First Quarter 2019 Financial Results and Provides Corporate Update

    Dermira Reports First Quarter 2019 Financial Results and Provides Corporate Update

  • Business Wire2 months ago

    Dermira to Report First Quarter 2019 Results and Host Conference Call on Tuesday, May 7, 2019

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, will report financial results for the quarter ended March 31, 2019 and provide an operational update after market close on Tuesday, May 7, 2019. Dermira also has early-stage research and development programs in other areas of dermatology.

  • Dermira (DERM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
    Zacks2 months ago

    Dermira (DERM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

    Dermira (DERM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Zacks2 months ago

    NASDAQ Back Above 8,000

    NASDAQ Back Above 8,000

  • Here's Why Dermira Shot Up 62% in March
    Motley Fool3 months ago

    Here's Why Dermira Shot Up 62% in March

    Results from a mid-stage study with a potential new eczema drug gave investors a reason to cheer.

  • Business Wire3 months ago

    Dermira to Present at the 18th Annual Needham Healthcare Conference

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that company management will participate in a fireside chat at the 18th Annual Needham Healthcare Conference on Wednesday, April 10, 2019 at 12:50 p.m. ET. Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. Dermira is committed to understanding the needs of both patients and physicians and using its insight to identify, develop and commercialize leading-edge medical dermatology products.

  • Does The Dermira, Inc. (NASDAQ:DERM) Share Price Fall With The Market?
    Simply Wall St.3 months ago

    Does The Dermira, Inc. (NASDAQ:DERM) Share Price Fall With The Market?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you're interested in Dermira, Inc. (NASDAQ:DERM), then you might want to consider its beta (a measure of share price volat...

  • GlobeNewswire3 months ago

    Dermira Announces “Life Unfolds” Direct-to-Consumer Campaign to Highlight QBREXZA™ (glycopyrronium) Cloth

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, today announced the launch of “Life Unfolds,” a new direct-to-consumer creative campaign designed to generate awareness of QBREXZA™ (glycopyrronium) cloth as a potential treatment option for people living with primary axillary hyperhidrosis, commonly known as excessive underarm sweating. QBREXZA, the first and only, once-daily, topical prescription anticholinergic, is approved by the U.S. Food and Drug Administration (FDA) to treat adult and pediatric patients 9 years of age and older living with this chronic, medical skin condition.

  • GlobeNewswire3 months ago

    Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    MENLO PARK, Calif., March 22, 2019 -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering.

  • Dermira (DERM) Catches Eye: Stock Jumps 12%
    Zacks3 months ago

    Dermira (DERM) Catches Eye: Stock Jumps 12%

    Dermira (DERM) saw a big move last session, as its shares jumped nearly 12% on the day, amid huge volumes.

  • GlobeNewswire3 months ago

    Dermira Prices $130.0 Million Public Offering of Common Stock

    MENLO PARK, Calif., March 19, 2019 -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering.

  • Why Dermira Stock Jumped Again Today
    Motley Fool3 months ago

    Why Dermira Stock Jumped Again Today

    An analyst's upgrade provides another boost to the high-flying biotech stock.

  • Company News For Mar 19, 2019
    Zacks3 months ago

    Company News For Mar 19, 2019

    Companies in the news are: OSTK, FIS, WP, EW and DERM

  • Can Dermira Stock Keep Soaring?
    Motley Fool3 months ago

    Can Dermira Stock Keep Soaring?

    The skincare specialist's experimental eczema treatment hit the mark in mid-stage testing, but what about the road ahead?